Klaus Schollmeier

Directeur/Membre du Conseil chez HEIDELBERG PHARMA AG

Profil

Currently, Klaus Schollmeier is Chairman at Anergis SA, Eternygen GmbH, and TACALYX GmbH; Chairman-Supervisory Board at Inthera Bioscience AG; Member-Supervisory Board at Heidelberg Pharma AG, Minaris Regenerative Medicine GmbH, Novaliq GmbH; and Independent Member-Supervisory Board at CureVac NV.
Formerly, the roles include Chief Executive Officer at SuppreMol GmbH (2013–2015), Chairman at Santhera Pharmaceuticals Holding AG (2011–2012), Chairman at PCOVERY ApS, Managing Director at ING BHF-Bank AG, Senior Director-Biotechnology at BASF Bioresearch Corp.
(1989–1993), Director at Graffinity Pharmaceuticals AG, Principal at Knoll AG and Abbott GmbH (Germany), Research Associate Professor-Medical School at Boston University, General Manager at BASF Pharma (1996–1998), and Member-Supervisory Board at Modra Pharmaceuticals BV.
Education includes a doctorate from Heinrich-Heine-Universität Düsseldorf conferred in 1991.

Postes actifs de Klaus Schollmeier

Sociétés	Poste	Début
CUREVAC	Directeur/Membre du Conseil	22/06/2022
HEIDELBERG PHARMA AG	Directeur/Membre du Conseil	15/05/2025
Minaris Regenerative Medicine GmbH	Directeur/Membre du Conseil	-
Eternygen GmbH	Président	-
TACALYX GmbH	Président	05/11/2020
Inthera Bioscience AG	Président	-
Anergis SA	Président	-
Novaliq GmbH	Directeur/Membre du Conseil	-

Anciens postes connus de Klaus Schollmeier

Sociétés	Poste	Fin
ING BHF-Bank AG	Corporate Officer/Principal	06/12/2018
░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░	░░░░░░░░░░	-
░░░░ ░░░░░░	░░░░░░░░░	░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░